Table 1.
Baseline Characteristics
| Characteristics | Casirivimab/Imdevimab, n = 16 (34%) | Sotrovimab, n = 31 (66%) | Total Cohort, N = 47 |
|---|---|---|---|
| Age, y, median (range) | 48.5 (21-78) | 50 (19-70) | 50 (19-78) |
| Male, n (%) | 8 (50) | 18 (58) | 26 (55) |
| Time from KT, mo, median (range) | 57.5 (1-348) | 70 (1-279) | 61 (1-348) |
| Comorbid condition | |||
| Hypertension, n (%) | 9 (56) | 22 (71) | 31 (66) |
| Diabetes, n (%) | 8 (50) | 8 (26) | 16 (34) |
| Cardiovascular history, n (%) | 1 (6) | 4 (13) | 5 (11) |
| Obesity, n (%) | 1 (6) | 4 (13) | 5 (11) |
| Baseline eGFR, mL/min/1.73 m2, median (range) | 51.5 (10-105) | 56 (11-121) | 56 (10-121) |
| Maintenance immunosuppression | |||
| Tac-MMF-steroids, n (%) | 11 (69) | 23 (74) | 34 (72) |
| Prior anti-SARS-CoV-2 vaccination | |||
| At least 2 doses,a n (%) | 13 (81) | 26 (84) | 39 (83) |
| Three doses, n (%) | 1 (6) | 16 (52) | 17 (36) |
| Time from the last dose, d, median (range) | 117 (39-211) | 103.5 (29-274) | 113 (29-274) |
| Documented humoral response,b n (%) | 10 (77) | 20 (77) | 30 (77) |
| Anti-RBD antibody titer, BAU/mL, median (range) | 199.7 (1-257) | 257 (1-257) | 257 (1-257) |
Abbreviations: BAU, binding antibody units; eGFR, estimated glomerular filtration rate; KT, kidney transplant; MMF, mycophenolate mofetil; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tac, tacrolimus.
a
One patient received 1 dose of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson).
b
Percentages were calculated among vaccinated patients (at least 2 doses; n = 39). Positivity, anti-RBD antibody titer >0.8 BAU/mL.